Format

Send to

Choose Destination
J Small Anim Pract. 2008 Jun;49(6):295-301. doi: 10.1111/j.1748-5827.2008.00545.x. Epub 2008 Apr 14.

Efficacy and safety of cefovecin for the treatment of urinary tract infections in cats.

Author information

1
Pfizer Animal Health, Pfizer Ltd., Ramsgate Road, Sandwich, Kent CT13 9NJ.

Abstract

OBJECTIVES:

To determine the efficacy and safety of cefovecin (Convenia); Pfizer Animal Health) in the treatment of urinary tract infections in cats.

METHOD:

A multi-centre, masked, randomised study was conducted in cats presenting with clinical signs indicative of urinary tract infections. Cephalexin (Rilexine); Virbac) administered orally twice daily at 15 mg/kg bodyweight for 14 days was compared with a single subcutaneous injection of cefovecin in cats. The primary efficacy parameter assessed was bacterial elimination of the pretreatment uropathogen.

RESULTS:

Four hundred and thirty-four cats were screened for urinary tract infections. One hundred and eighty-five cats were treated with either cefovecin (n=124) or cephalexin (n=61). Ninety-seven cats (22.2 per cent) had confirmed bacteriuria and 82 cats were included in efficacy analysis. Escherichia coli was eliminated in 76.7 per cent (23 of 30) of cefovecin-treated cats compared with 62.5 per cent (10 of 16) of cephalexin-treated cats. Cefovecin demonstrated statistical non-inferiority compared with cephalexin for bacterial elimination. There were no suspected adverse drug reactions attributable to treatment with cefovecin or cephalexin.

CLINICAL SIGNIFICANCE:

Cefovecin was demonstrated to be an effective and safe treatment for urinary tract infections.

Comment in

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center